New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 11, 2013
14:21 EDTCCMPCabot Microelectronics downgraded to Neutral from Buy at DA Davidson
News For CCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 28, 2015
05:57 EDTCCMPCabot Microelectronics to host conference call
Subscribe for More Information
05:32 EDTCCMPCabot Microelectronics agrees to acquire NexPlanar Corporation
Cabot Microelectronics announced that it has entered into a definitive agreement to acquire NexPlanar Corporation, a privately-held, U.S. based company that specializes in the development, manufacture and sale of advanced CMP pad solutions for the semiconductor industry. Under the acquisition agreement, Cabot Microelectronics will purchase 100% of the stock of NexPlanar for a purchase price of approximately $142M, plus up to an additional $2.3M depending upon treatment of certain unvested stock options held by NexPlanar security holders. At closing, NexPlanar is expected to have approximately $15M of cash and no debt. The company intends to fund the acquisition from its available cash balance. Cabot Microelectronics' acquisition of NexPlanar is directly aligned with its strategy to strengthen and grow its core CMP consumables business, and in particular, CMP pads. NexPlanar has established meaningful supply positions with technology leading customers for advanced technology node applications. The Company expects that NexPlanar's innovative ElementTM thermoset polyurethane CMP pad technology will complement its own EpicTM thermoplastic polyurethane technology. In addition to expanding its pad product portfolio, Cabot Microelectronics anticipates that the acquisition will leverage the company's existing global sales and technology infrastructure, as well as its supply chain capabilities and quality systems. Cabot Microelectronics expects to close the transaction within 30 to 45 days, subject to customary closing conditions and regulatory approvals.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use